This multipronged approach extends to intercepting pathways that tumors may exploit to evade VEGF inhibitor effects, with regorafenib maintaining its anti-angiogenic stance even against VEGF-resistant tumor cells. The gene discussed is VEGFA; the disease is neoplasm.